J Karagianis

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study
    J Karagianis
    Eli Lilly Canada Inc, Toronto, ON, Canada
    Int J Clin Pract 64:1520-9. 2010
  2. ncbi Re: Evolutionary perspectives on schizophrenia
    Jamie Karagianis
    Can J Psychiatry 48:641. 2003
  3. ncbi A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study
    J Karagianis
    Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Schizophr Res 113:41-8. 2009
  4. ncbi Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients
    J Karagianis
    Clinical Research, Eli Lilly Canada Inc, Toronto, ON, Canada M1N 2E8
    Int J Clin Pract 63:1578-88. 2009
  5. ncbi The potential role of appetite in predicting weight changes during treatment with olanzapine
    Michael Case
    Lilly USA, LLC, Indianapolis, IN, USA
    BMC Psychiatry 10:72. 2010
  6. ncbi Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia
    Jamie Karagianis
    Eli Lilly Canada Inc, Toronto, ON, Canada
    Curr Med Res Opin 25:2121-32. 2009
  7. ncbi Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
    Jamie Karagianis
    Clinical Research, Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Hum Psychopharmacol 23:275-81. 2008
  8. ncbi Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools
    Jamie Karagianis
    Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Curr Med Res Opin 23:2551-7. 2007
  9. ncbi Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania
    R Chandrasena
    Department of Psychiatry, University of Western Ontario, Chatham, Ontario, Canada
    Int J Clin Pract 63:1249-58. 2009
  10. ncbi Can increased food intake improve psychosis? A brief review and hypothesis
    T Treuer
    Area Medical Center Vienna, Eli Lilly and Company, Austria
    Curr Mol Pharmacol 1:270-2. 2008

Detail Information

Publications16

  1. ncbi An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study
    J Karagianis
    Eli Lilly Canada Inc, Toronto, ON, Canada
    Int J Clin Pract 64:1520-9. 2010
    ....
  2. ncbi Re: Evolutionary perspectives on schizophrenia
    Jamie Karagianis
    Can J Psychiatry 48:641. 2003
  3. ncbi A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study
    J Karagianis
    Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Schizophr Res 113:41-8. 2009
    ....
  4. ncbi Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients
    J Karagianis
    Clinical Research, Eli Lilly Canada Inc, Toronto, ON, Canada M1N 2E8
    Int J Clin Pract 63:1578-88. 2009
    ..To describe the Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO) patient population at study entry, focusing on illness burden and prescribing practices across regions...
  5. ncbi The potential role of appetite in predicting weight changes during treatment with olanzapine
    Michael Case
    Lilly USA, LLC, Indianapolis, IN, USA
    BMC Psychiatry 10:72. 2010
    ..Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite...
  6. ncbi Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia
    Jamie Karagianis
    Eli Lilly Canada Inc, Toronto, ON, Canada
    Curr Med Res Opin 25:2121-32. 2009
    ..The purpose of the study was to compare effectiveness of antipsychotic treatment as measured by 1-year treatment completion rates...
  7. ncbi Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
    Jamie Karagianis
    Clinical Research, Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Hum Psychopharmacol 23:275-81. 2008
    ..The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine...
  8. ncbi Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools
    Jamie Karagianis
    Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Curr Med Res Opin 23:2551-7. 2007
    ....
  9. ncbi Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania
    R Chandrasena
    Department of Psychiatry, University of Western Ontario, Chatham, Ontario, Canada
    Int J Clin Pract 63:1249-58. 2009
    ..This study compared the safety, tolerability and switch to oral medication in patients with bipolar disorder or schizophrenia who received intramuscular (IM) olanzapine or other IM antipsychotics for the treatment of acute agitation...
  10. ncbi Can increased food intake improve psychosis? A brief review and hypothesis
    T Treuer
    Area Medical Center Vienna, Eli Lilly and Company, Austria
    Curr Mol Pharmacol 1:270-2. 2008
    ..More research is needed to evaluate this potential link. However, basic animal research and evolutionary approaches can provide insights into metabolic disturbances associated with schizophrenia...
  11. ncbi Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies
    C J Bushe
    Eli Lilly and Company Ltd, Basingstoke, UK
    Int J Clin Pract 63:1743-61. 2009
    ....
  12. ncbi The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs
    D Novick
    European Outcomes Research, Eli Lilly and Co, Surrey, UK
    Pharmacopsychiatry 43:81-5. 2010
    ....
  13. ncbi Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study
    Cecilia Adrianzén
    Eli Lilly Perú, Lima, Peru
    Hum Psychopharmacol 25:439-47. 2010
    ..To explore the relative association of adverse events with health-related quality of life (HRQL) in patients (N = 16 091) with schizophrenia, treated with antipsychotic medication...
  14. ncbi Parasitosis, dopaminergic modulation and metabolic disturbances in schizophrenia: evolution of a hypothesis
    Tamas Treuer
    Neuroscience Research, Area Medical Center Vienna, Eli Lilly Regional GmbH, Venna, Austria
    Neuro Endocrinol Lett 28:535-40. 2007
    ..We believe this model may well open up new avenues of research in the discovery of drugs to counteract schizophrenia...
  15. ncbi What do we know about insulin resistance and glucose metabolism in patients with schizophrenia treated with antipsychotics?
    Jamie Karagianis
    J Clin Psychiatry 68:799-800; author reply 801-2. 2007
  16. ncbi Case report: edema related to olanzapine therapy
    Dorian Deshauer
    Royal Ottawa Hospital in Ontario
    Can Fam Physician 52:620-1. 2006